OTC Drugs Of Abuse Test Product Labeling Should State SAMHSA Limitations
This article was originally published in The Gray Sheet
Executive Summary
Labeling for over-the-counter drugs of abuse tests should "clearly and explicitly" state what drugs the system will and will not test, Benjamin Gerson, MD, told the FDA on behalf of the American Society of Clinical Pathologists at a June 19 public hearing in Rockville, Maryland.